STOCK TITAN
  1. Home
  2. News
  3. DGX

Quest Diagnostics, Inc. - DGX STOCK NEWS

Welcome to our dedicated news page for Quest Diagnostics (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

News
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Quest Diagnostics Incorporated (NYSE: DGX) to Present at J.P. Morgan Healthcare Conference, Offering Insight into Company Strategy and Market Trends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
News
Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) announced the appointment of Yuri A. Fesko, M.D., as senior vice president and chief medical officer. Dr. Fesko, a seasoned healthcare executive, will oversee medical affairs, clinical development, and health plan policy support for new services and care delivery models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
News
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) and Scipher Medicine Announce Collaboration to Expand Precision Medicine for Rheumatoid Arthritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
News
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) unveils new confirmatory testing service for novel psychoactive substances (NPS) with 88 compounds, including xylazine and acetyl fentanyl. The Health Trends® report found xylazine in 1 in 12 specimens tested, indicating a rising polysubstance crisis in America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
News
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index for Seventh Consecutive Year
Rhea-AI Summary
Quest Diagnostics (DGX) Receives 100% Score on Corporate Equality Index for Seventh Consecutive Year
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
News
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer
Rhea-AI Summary
Haystack Oncology (DGX) collaborates with Rutgers Cancer Institute of New Jersey to use Haystack MRD™ technology for a clinical trial on early-stage triple-negative breast cancer patients. The technology aims to provide molecular insights and evaluate therapeutic response, potentially leading to better outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
clinical trial
News
Quest Diagnostics Multi-Pronged Approach to Waste Reduction
Rhea-AI Summary
Quest Diagnostics (DGX) aims to implement a waste-to-energy strategy, reduce medical waste, and improve water stewardship by 2025. The company has already made significant progress in waste reduction, plastic waste reduction, paper waste reduction, and water use efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
News
New Report From Quest Diagnostics Unveils Priorities for Community Health Centers
Rhea-AI Summary
Quest Diagnostics (DGX) collaborates with Community Health Centers to address current healthcare needs among underserved populations. The company surveyed FQHC leaders and found that staffing, nontraditional care services, and operational/financial concerns are the main challenges. Quest aims to support health centers in providing comprehensive care by breaking down affordability barriers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
News
Universal DX Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
Rhea-AI Summary
UDX (Universal DX) announces a strategic collaboration with Quest Diagnostics (DGX) and the initial closing of its series B financing of approximately $70 million. The collaboration aims to improve colorectal cancer screening in the United States by combining UDX's Signal-C® technology with Quest's expertise and national scale. The company plans to pursue FDA premarket approval for its colorectal cancer screening blood test and enroll patients in a 15,000-patient study. The test has shown 93% sensitivity for colorectal cancer detection and 54% sensitivity for detection of precancerous lesions at 92% specificity overall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
News
Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been awarded a multi-year contract by the CDC to assess the burden of hepatitis C virus (HCV) in the United States. The company will provide research consulting, laboratory testing, and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Stock DGX logo
Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

#633 Ranked by Market Cap
#2771 Ranked by Stock Gains
#1310 Ranked by Dividends

DGX Stock Data

14.27B
109.71M
0.43%
91.73%
2.29%
Medical Laboratories
Health Care and Social Assistance
Link
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator